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Abstract: To obtain new analogs of peptide nucleic acids (PNAs), synthesis of the building block 14 has been achieved. Building 
block 14 has been derived from the coupling of the isothiocyanate derivative, 12 with 13. Isothiocyanate derivative 12 was 
obtained from S-aspartic acid derivative 5 in a number of steps. © 1998 Elsevier Science Ltd. All rights reserved. 
During the past several years, peptide nucleic acids (PNAs, Figure 1, 1) have appeared to be useful mimics 
of DNA with promising applications in diagnostics and in the pharmaceutical area (e.g. antisense-antigene 
therapeutic agents). 2 Unlike DNA/RNA, PNA is an achiral, neutral molecule in which nucleobases are attached to 
the achiral backbone derived from N-(2-aminoethyl)glycine derivative (2). The synthesis of PNA could be easily 
achieved through peptide chemistry by using a building block methodology on solid phase. 3 PNA has shown to 
exhibit excellent hybridization and sequence specific properties to single-stranded (ss) DNA and RNA. It is also 
known to tbrm stronger triplexes with double-stranded (ds) DNA. The strong binding of PNA with ssDNA, 
dsDNA and RNA has been attributed to its neutral character and to the flexible nature of the polyamide backbone, 
in combination with the rigidity of the amide bond in the backbone. Various studies on the flexibility of PNA have 
indicated that the N-(2-aminoethyl)glycine backbone provides optimal binding capabilities. 2,4a However, very 
little has been studied to explore the importance of the rigidity of an amide bond within a backbone on binding 
properties of PNA.  2,4b-d 
Despite having several advantages, i.e. enzymatic stability, stronger and sequence-specific binding to 
ssDNA, dsDNA and RNA, ease of synthesis using solid phase methodology, its limited solubility at physiological 
pH, and passive transportation across the cell membrane are the two major limitations that are associated with 
PNA. 2,5 Moreover, hybridization of PNA with a ssDNA to form a PNA/ssDNA/PNA triplet (antigene strategy) at 
physiological salt concentration is not efficient. The formation of stable PNA/ssDNA/PNA triplex occurs only at 
low salt concentrations and is restricted to PNAs having a high pyrimidine content. 6 
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To overcome the problems that are associated with PNA, the objective of our research is to incorporate 
modifications into the polyamide backbone of PNAs and explore its effects on the binding properties with 
DNA/RNA and on the transportation across the cell membranes. Our goal is to enhance the rigidity of the 
polyamide backbone by the incorporation of  thiourea or guanidinium functional group (for PNA analogs, see 
Figure 1, 3). Synthesis of  PNA analogs, 3, could be achieved using a building block 2 (required for the 
synthesis of PNA) and 4 on a solid phase. Using this approach, it would be possible to systematically control the 
rigidity of the polyamide backbone. Moreover, transformation of the thiourea to a guanidinium salt could easily be 
obtained within the backbone. Such a transformation would allow an enhancement in the solubility of the PNA 
analog at the physiological pH due to the incorporation of a positive charge into the backbone. Applications of 
cationic DNA analogs for stronger bindings with RNA or DNA are just appearing in the literature and a positively 
charged analog of PNA could open new opportunities in the area of antisense/antigene technology. 7 
Herein, we describe our approach for the synthesis of building blocks 12 and 14 (pyrimidine derivative as 
a base) required for the solid phase synthesis of PNA analogs. Building block 12 was obtained from a S-aspartic 
acid der ivat ive ,  5, in the fol lowing steps. [3-Amino alcohol  6 ( S c h e m e  1) was der ived from N- 
(butyloxycarbonyl)-S-aspartic acid mono-t-butyl ester (5) by the NaBH4 reduction of the mixed anhydride (iso- 
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Scheme 1: (a) I.l eq iso-BuOCOCl, NMM, THF, 0 °C; (b) 3 eq NaBH4, 0 °C MeOH; (c) TsCI, Pyr, rt; (d) 2.5 eq 
NaCN, DMSO, 80 °C; (e) 2M NaOH, MeOH, rt; (f) 1.I eq iso-BuOCOCl, NMM, DME, -15 °C; (g) 3 eq NaBH4, H20, -15 
°C; (h) TBDMSC1, imidazole, rt; (i) 0.4 eq COC12.6H20, MeOH, 10 eq NaBH4, -15 °C; (j) 10% K2CO3, Dioxane, 1.2 cq 
CBzC1; (k) 1.2 eq Bu4NF, THF, rt; (t) Ph3P, CBr4, THF, rt; (m) 3 eq Thymine, 3 eq K2CO3, Bu4NI (cat), DMF, 80 °C; 
(n) H2, 10% Pd/C, MeOH; (o) 1.2 eq FmocCl, 10% K2CO3, CH3CN. 
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Scheme 2: (a) TFA, CH2CI 2, 0 °C; (b) DIPC, THF, CS 2, 0 °C; (c) CH2C12, DMF, 40 °C. 
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BuOCOC1, N-methylmorpholine inTHF) in 90% yield. 8 Alcohol derivative 6 was converted to the corresponding 
nitrile 7 in two steps (80% yield): (i) tosyl chloride (pyridine, CH2CI2), and (ii) NaCN, DMSO at 80 oc.9 Mild 
hydrolysis (2M NaOH, methanol) of  7, followed by the NaBH4 reduction of the mixed anhydride yielded 8 in 
82% yield. Compound 8 was converted to 9 in the sequential order: (i) protection of the primary hydroxyl group 
(TBDMSC1, imidazole, rt); (ii) reduction of the nitrile group (NaBH4, COC12-H20, MeOH); 10 (iii) protection of  the 
amino group (CBzC1, K2CO3, Dioxane); (iv) deprotection of  the hydroxyl group, and finally, (v) conversion of 
the primary hydroxyl group to the bromo derivative (Ph3P, CBr4, rt). Using alkylation reaction conditions as 
described by Taddei, 4c nucleophilic substitution of a nucleobase (i.e., thymine) gave the desired compound 10a 
(60% yield) and a side product, 10b (32% yield). The required building block, 11 was obtained from 10a in two 
steps: (i) conversion of  NHCBz to NH2 (H2, 10% Pd/C, MeOH), and (ii) the protection of  NH2 to NHFmoc 
(FmocC1, 10% K2CO 3, CH3CN ). The thiourea dinucleotide building block 14 was obtained from the 
isothiocyanate derivative of  11 through several steps. The butyloxycarbamate protective group of 11 was 
removed by the treatment with TFA/CH2C12 and was reacted with CS2, DIPC/THF that afforded the isothiocyanate 
derivative 12 (Scheme 2).1 l The thiourea dinucleotide methyl ester building block, 14 was obtained in 39%. 
isolated yield (purified by RP-HPLC) from the coupling of isothiocyanate derivative 12 with the PNA thymine 
monomer  13 (40 oc).12 In a similar manner, the isothiocyanate 12 could also be coupled with other PNA 
monomers having different pyrimidine and purine bases to obtain new building blocks for the synthesis of PNA 
analogs. 
To summarize, a successful synthesis of the methyl ester of building block 14, required tbr the solid phase 
metholodology to obtain PNA anlogs, has been achieved. Further, incorporation of the building block 14 for 
various derivatives of modified PNAs to explore their properties are currently under investigation. 
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